ZAI LAB LIMITED (ZLAB) Operating Margin
- Operating margin · 12 months: Value -59.52%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -59.52% | Operating income / revenue. Period ending 2026-06-30. $-264.10M ÷ $443.75M × 100 ≈ -59.52% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -264.10M USD | Operating Income (Loss) |
| Revenue | 443.75M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 195.54M USD | Cost of Goods and Services Sold |
| Research and development | 236.92M USD | Research and Development Expense |
| Selling, general and administration | 281.09M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-264.10M | $443.75M | $195.54M | $236.92M | $281.09M | -59.52% |
| 2026-03-31 | $-242.51M | $447.09M | $190.38M | $225.77M | $279.25M | -54.24% |
| 2025-12-31 | $-229.43M | $457.18M | $190.52M | $220.90M | $277.61M | -50.18% |
| 2025-09-30 | $-227.92M | $438.61M | $170.00M | $211.52M | $287.18M | -51.96% |
| 2025-06-30 | $-246.95M | $425.09M | $159.81M | $229.58M | $284.30M | -58.09% |
| 2025-03-31 | $-268.12M | $416.12M | $151.95M | $240.59M | $292.97M | -64.43% |
| 2024-12-31 | $-282.12M | $397.61M | $147.12M | $234.50M | $298.74M | -70.95% |
| 2024-09-30 | $-338.21M | $354.93M | (m) | $264.20M | $298.75M | -95.29% |
| 2024-06-30 | $-353.92M | $322.31M | (m) | $256.99M | $300.08M | -109.81% |
| 2024-03-31 | $-367.36M | $291.07M | (m) | $272.04M | $288.29M | -126.21% |
| 2023-12-31 | $-366.57M | $266.72M | (m) | $265.87M | $281.61M | -137.44% |
| 2023-09-30 | $-339.88M | $262.93M | (m) | $250.87M | $271.01M | -129.27% |
| 2023-06-30 | $-384.90M | $250.66M | (m) | $291.62M | $269.01M | -153.55% |
| 2023-03-31 | $-394.12M | $229.37M | (m) | $281.03M | $264.49M | -171.82% |
| 2022-12-31 | $-404.36M | $212.67M | (m) | $286.41M | $258.97M | -190.13% |
| 2022-09-30 | $-526.26M | $194.60M | (m) | $391.55M | $256.52M | -270.44% |
| 2022-06-30 | $-480.88M | $180.74M | (m) | $347.17M | $248.97M | -266.07% |
| 2022-03-31 | $-552.74M | $170.10M | (m) | $423.31M | $239.98M | -324.95% |
| 2021-12-31 | $-700.06M | $144.10M | (m) | $573.31M | $218.83M | -485.80% |
| 2021-09-30 | $-576.12M | $115.23M | (m) | $463.78M | $190.22M | -499.96% |
| 2021-06-30 | $-569.18M | $86.78M | (m) | $466.74M | $159.09M | -655.86% |
| 2021-03-31 | $-482.57M | $60.84M | (m) | $392.82M | $128.44M | -793.14% |
| 2020-12-31 | $-301.80M | $48.96M | (m) | $222.71M | $111.31M | -616.45% |
| 2020-09-30 | $-258.59M | $38.51M | (m) | $192.24M | $93.37M | -671.51% |
| 2020-06-30 | $-247.60M | $28.78M | (m) | $185.34M | $83.19M | -860.40% |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-203.20M | $12.98M | (m) | $142.22M | $70.21M | -1564.85% |
| 2019-09-30 | $-217.69M | (m) | (m) | $165.78M | $58.16M | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-141.77M | $129.45K | (m) | $120.28M | $21.58M | -109514.01% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-51.39M | (m) | (m) | $39.34M | (m) | (m) |
| 2016-12-31 | $-38.53M | (m) | (m) | $32.15M | (m) | (m) |
| 2015-12-31 | $-16.35M | (m) | (m) | $13.59M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |